Mareen

Doxepin, the active ingredient in Mareen, is a tricyclic antidepressant presented as an unknown strength/oral tablet for oral use. It treats major depressive disorder and related conditions such as anxiety, insomnia, and pruritus in adult patients.

GNH USA supplies Mareen as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mareen (doxepin) is used in the management of several psychiatric and dermatologic conditions.

- Major depressive disorder: alleviates depressive symptoms and improves mood in adults. - Anxiety disorders: reduces excessive worry and tension. - Insomnia: promotes sleep onset and maintenance. - Pruritus associated with dermatologic conditions: relieves itching and improves skin comfort.

Doxepin may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Drowsiness: feeling unusually sleepy or fatigued. - Dry mouth: reduced salivation leading to thirst. - Constipation: difficulty passing stool. - Dizziness: sensation of light‑headedness.

Serious or Rare Side Effects: - Cardiac arrhythmia: irregular heart rhythm that may require medical attention. - Seizures: convulsive episodes, especially at high doses. - Severe hypotension: marked drop in blood pressure causing faintness.

When prescribing doxepin, clinicians should consider several safety precautions.

- Cardiac monitoring: assess heart rhythm in patients with known cardiac disease. - Suicidal ideation: monitor for worsening depression or suicidal thoughts. - Elderly patients: use lower doses due to increased sensitivity to anticholinergic effects. - Discontinuation: avoid abrupt cessation to prevent withdrawal symptoms. - Store at ambient temperature: keep in the original pack, protect from moisture.

Doxepin can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis. - Selective serotonin reuptake inhibitors (SSRIs): increased serotonin syndrome risk. - Strong CYP2D6 inhibitors: elevated doxepin plasma levels.

Moderate Interactions (Monitor Closely): - Central nervous system depressants: additive sedation. - Antihypertensive agents: potential for excessive blood pressure lowering.